[go: up one dir, main page]

AU714209B2 - Method of cancer treatment by p53 protein control - Google Patents

Method of cancer treatment by p53 protein control Download PDF

Info

Publication number
AU714209B2
AU714209B2 AU26206/95A AU2620695A AU714209B2 AU 714209 B2 AU714209 B2 AU 714209B2 AU 26206/95 A AU26206/95 A AU 26206/95A AU 2620695 A AU2620695 A AU 2620695A AU 714209 B2 AU714209 B2 AU 714209B2
Authority
AU
Australia
Prior art keywords
protein
nucleic acid
lys
calpain
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU26206/95A
Other languages
English (en)
Other versions
AU2620695A (en
Inventor
Jean-Marie Blanchard
Serge Carillo
Marc Peichaczyk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Publication of AU2620695A publication Critical patent/AU2620695A/en
Application granted granted Critical
Publication of AU714209B2 publication Critical patent/AU714209B2/en
Assigned to AVENTIS PHARMA S.A. reassignment AVENTIS PHARMA S.A. Request to Amend Deed and Register Assignors: RHONE-POULENC RORER S.A.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU26206/95A 1994-05-31 1995-05-22 Method of cancer treatment by p53 protein control Ceased AU714209B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR94/06583 1994-05-31
FR9406583A FR2720277B1 (fr) 1994-05-31 1994-05-31 Méthode de traitement des cancers par régulation de la protéine P53.
PCT/FR1995/000670 WO1995033060A1 (fr) 1994-05-31 1995-05-22 Methode de traitement des cancers par regulation de la proteine p53

Publications (2)

Publication Number Publication Date
AU2620695A AU2620695A (en) 1995-12-21
AU714209B2 true AU714209B2 (en) 1999-12-23

Family

ID=9463670

Family Applications (1)

Application Number Title Priority Date Filing Date
AU26206/95A Ceased AU714209B2 (en) 1994-05-31 1995-05-22 Method of cancer treatment by p53 protein control

Country Status (8)

Country Link
EP (1) EP0763121A1 (sv)
JP (1) JPH10500978A (sv)
AU (1) AU714209B2 (sv)
CA (1) CA2190293C (sv)
FI (1) FI120501B (sv)
FR (1) FR2720277B1 (sv)
NO (1) NO321411B1 (sv)
WO (1) WO1995033060A1 (sv)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19518488C1 (de) * 1995-05-19 1996-10-10 Progen Biotechnik Gmbh Autoantigen, geeignet zur Feststellung einer Thromboseneigung
EP0799892A3 (en) * 1996-04-05 1998-08-12 Takeda Chemical Industries, Ltd. Calpain, its production and use
US6232454B1 (en) 1998-02-27 2001-05-15 Incyte Genomics, Inc. Human proteinase molecules
AU2344100A (en) * 1998-11-18 2000-06-05 Canji, Inc. Viral vectors with late transgene expression
AU2001247922A1 (en) * 2000-03-31 2001-10-15 Parker Hughes Institute Calpain inhibitors in cancer treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0159678A1 (en) * 1984-04-20 1985-10-30 The Cancer Institute Of Japanese Foundation For Cancer Research Use of 5-[(3,4-dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxy-phenyl)-2-isopropylvaleronitrile
WO1993002106A1 (en) * 1991-07-25 1993-02-04 The Mclean Hospital Corporation Neural calcium-activated neutral proteinase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0395309B1 (en) * 1989-04-28 1995-12-27 Takara Shuzo Co. Ltd. Human calpastatin-like polypeptide
JPH0641067A (ja) * 1992-04-20 1994-02-15 Kitasato Inst:The 新規カルパイン阻害物質ｋｐ−１２４１及びその製造法
EP0580161A1 (en) * 1992-07-22 1994-01-26 THE McLEAN HOSPITAL CORPORATION Prophylactic and therapeutic treatment of Alzheimer's disease
US5607831A (en) * 1993-03-25 1997-03-04 The United States Of America As Represented By The Department Of Health And Human Services In vitro methods for assessing the susceptibility of HIV-1-infected individuals to cysteine protease-mediated activation-induced programmed cell death

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0159678A1 (en) * 1984-04-20 1985-10-30 The Cancer Institute Of Japanese Foundation For Cancer Research Use of 5-[(3,4-dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxy-phenyl)-2-isopropylvaleronitrile
US4788219A (en) * 1984-04-20 1988-11-29 Cancer Institute, Japanese Foundation For Cancer Research Antimetastatic agent
WO1993002106A1 (en) * 1991-07-25 1993-02-04 The Mclean Hospital Corporation Neural calcium-activated neutral proteinase inhibitors

Also Published As

Publication number Publication date
FI120501B (sv) 2009-11-13
FI964783A0 (sv) 1996-11-29
FR2720277A1 (fr) 1995-12-01
EP0763121A1 (fr) 1997-03-19
CA2190293C (fr) 2011-06-28
WO1995033060A1 (fr) 1995-12-07
CA2190293A1 (fr) 1995-12-07
NO321411B1 (no) 2006-05-08
FI964783L (sv) 1996-11-29
JPH10500978A (ja) 1998-01-27
FR2720277B1 (fr) 1996-07-12
NO964772L (no) 1996-11-11
NO964772D0 (no) 1996-11-11
AU2620695A (en) 1995-12-21

Similar Documents

Publication Publication Date Title
CA2163256C (fr) Vecteurs adenoviraux d'origine animale et utilisation en therapie genique
US6143290A (en) Tumor regression by adenovirus expression of wild-type p53
CA2836987A1 (en) Chimeric adenoviruses for use in cancer treatment
AU724324B2 (en) p16 expression constructs and their application in cancer therapy
AU714209B2 (en) Method of cancer treatment by p53 protein control
EP0719328B1 (fr) Gene grb3-3, ses variants et leurs utilisations
US7772367B2 (en) C-terminal p53 palindromic peptide that induces apoptosis of cells with aberrant p53 and uses thereof
US20010014319A1 (en) Recombinant viruses expressing lecithin-cholesterol acyltransferase, and uses thereof in gene therapy
KR101756131B1 (ko) 간세포 성장인자 및 기질세포 유발인자1알파를 이용한 말초동맥질환의 예방 또는 치료용 조성물
AU730324B2 (en) Use of protein gax for treating cancer
WO1999055831A2 (en) Adenoviral vectors for treating disease
US7837991B2 (en) Method of cancer treatment by p53 protein control
KR102566745B1 (ko) 암의 예방 또는 치료를 위한 Runx3 변이 단백질
MXPA96005522A (en) Method for the treatment of cancer through the control of protein
US7273854B1 (en) Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative disorders
FR2771423A1 (fr) Vecteurs permettant d'inhiber ou retarder la liaison d'un virus d'immunodeficience et/ou sa penetration dans une cellule cible
Bernloehr et al. Efficient propagation of single gene deleted recombinant Sendai virus vectors
FR2734826A1 (fr) Deltap62, ses variants, sequences nucleiques et leurs utilisations
Connelly Adenoviral vectors
EP0734447A1 (fr) Modele animal de la maladie d'alzheimer, preparation et utilisations
WO2003062373A2 (en) Methods and materials for the recruitment of endothelial cells
JP2006524712A (ja) カテプシンの阻害のための方法および組成物
WO2022186282A1 (ja) 糖尿病に対するｈｂ－ｅｇｆ遺伝子治療
KR101607282B1 (ko) 유리형 산화환원조절단백-1 및 이를 함유하는 항염증 약학조성물
Gianfranceschi et al. Inhibition of exogenous mRNA translation in a cell-free system by chromatin peptides from calf thymus

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)